Back to Agenda
Session 11: From Qualitative to Quantitative, Practical Frameworks for Benefit-Risk Decisions
Session Chair(s)
Michael Von Forstner, PhD, MPH, MSc
Managing Director, Head of Pharmacoepidemiology Practice, Mesa Laubela Consulting, Switzerland
Balmeet Gurm, MD
Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety, Bristol Myers Squibb, United States
This session explores the evolution of structured benefit-risk assessment and how organizations are building practical frameworks to support transparent, consistent, science-driven decision making across the product lifecycle. Speakers will show how qualitative, semi-quantitative, and quantitative approaches come together to strengthen regulatory communications, risk management, and benefit-risk evaluations, using a real-world framework developed at BMS as a case study.
Have an account?